PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals (“Calando”), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today the online publication in the journal Shock of the first investigation of siRNA formulated with Calando’s RONDEL™ nucleic acid delivery technology for the treatment of sepsis in mice. This work was done in collaboration with Dr. Richard Hotchkiss and colleagues in the School of Medicine at Washington University in St. Louis. RONDEL™-mediated delivery of anti-apoptotic siRNA to lymphocytes of septic mice is shown to reverse the depletion of immune cells that is a hallmark of this disease.
